Flerie

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions through synthetic biology. Established in 2007, Prokarium focuses on creating innovative microbial immunotherapy treatments, particularly in the oncology sector. Its product pipeline includes Vaxonella, which is designed to stimulate immune responses by utilizing the unique properties of the gastrointestinal tract. Additionally, the company is developing vaccines for various infectious diseases, including Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. Prokarium's lead program is aimed at revolutionizing the treatment of bladder cancer by fostering immune-driven, long-lasting antitumor effects, thereby offering new therapeutic options for healthcare providers in combating cancer and infectious diseases.

Lipum AB is a clinical-stage biopharmaceutical company based in Umeå, Sweden, focused on developing innovative treatments for chronic inflammatory diseases. The company's lead candidate, SOL-116, is a humanized antibody designed to target a previously unexplored molecule in the immune system, offering potential benefits over existing therapies. Lipum's biological treatments aim to alleviate symptoms for patients who do not respond or only respond temporarily to current TNF-alpha inhibitors. The company is particularly dedicated to treating rheumatoid arthritis, a debilitating autoimmune disease, and juvenile idiopathic arthritis, a rare condition affecting children. Lipum also investigates treatments for other chronic inflammatory conditions, including Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis, with the goal of reducing dependency on corticosteroids and immunosuppressants while minimizing adverse effects.

Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

XNK Therapeutics is a clinical-stage biotechnology company based in Stockholm, Sweden, specializing in immunotherapy for cancer prevention and treatment. The company is focused on developing innovative autologous natural killer (NK) cell-based therapies using its proprietary technology platform. XNK Therapeutics has positioned itself as a leader in the clinical development and manufacture of these therapies, which are designed to effectively target cancers, particularly in scenarios where allogeneic cell products may not be suitable. By harnessing the unique properties of its investigational drug candidates, XNK Therapeutics aims to play a crucial role in advancing cancer treatment strategies.

Geneos Therapeutics, Inc. is a biotechnology company that specializes in the development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and located in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies based on the unique tumor mutations of individual patients. By identifying relevant neoantigen targets from each patient's tumor, Geneos aims to develop innovative treatments that provide targeted immunotherapy options for various types of cancer. This approach is designed to empower oncologists with tailored solutions to improve patient outcomes in cancer treatment.

Strike Pharma is a biotechnology company focused on developing personalized cancer treatments through its proprietary Adaptable Drug Affinity Conjugate (ADAC) technology. This innovative approach utilizes an antibody-based method tailored to the genetic profile of each patient's tumor, enabling targeted destruction of cancer cells while sparing healthy cells. By providing scalable personalized immunotherapy, Strike Pharma aims to deliver affordable and effective treatment options for cancer patients, significantly reducing the risk of adverse side effects associated with traditional therapies.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Synerkine Pharma is engaged in the development of innovative fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's focus lies in targeting common regulatory mechanisms associated with various forms of chronic pain. Its fusion proteins possess distinctive properties that help normalize pain and inhibit inflammation, thereby offering potential solutions for patients suffering from different pain types. Through its research and development efforts, Synerkine Pharma seeks to provide pharmaceutical products that effectively reduce pain, as demonstrated in multiple pre-clinical models.

Amarna Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, focused on developing innovative viral vector-based therapies and vaccines. Founded in 2008, the company utilizes its proprietary SVac platform to create next-generation gene and immune therapies targeting a variety of conditions, including allergies, genetic disorders, cancer, and autoimmune diseases. Amarna Therapeutics aims to improve patients' life expectancy and quality of life while also reducing healthcare costs through effective and potentially curative interventions. To achieve its goals, the company has established strategic partnerships with leading research institutions and organizations in virology, vector production, immunology, ophthalmology, oncology, and neurology, fostering collaboration in the advancement of gene therapy technologies.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on treating inflammatory disorders by enhancing epithelial barrier integrity, a crucial factor in various diseases. Epithelial cells comprise significant components of human skin, lung tissue, the intestinal tract, and genitalia, with compromised barrier integrity linked to persistent inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates aimed at addressing the substantial global burden of chronic respiratory diseases and other unmet medical needs. Its lead candidate, EP395, is designed to be the first oral, disease-modifying, non-antibiotic macrolide that strengthens barriers and reduces inflammation, targeting conditions such as chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases. Through its innovative approach, EpiEndo seeks to provide effective treatments that improve patient outcomes.

KAHR Medical Ltd., established in 2005 and headquartered in Jerusalem, Israel, is a biopharmaceutical company specializing in immuno-oncology drug development. It focuses on creating fusion protein pharmaceuticals for treating cancer and autoimmune diseases. KAHR's proprietary technology involves developing 'third generation biological drugs,' which are unique fusion-protein molecules designed to activate immune responses by converting cancer cells' protective mechanisms into targets for the immune system. The company offers several candidates, including DSP105 and DSP106 for T-cell mediated tumor destruction, and DSP107 targeting CD47 tumors while delivering an immune costimulatory signal.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions through synthetic biology. Established in 2007, Prokarium focuses on creating innovative microbial immunotherapy treatments, particularly in the oncology sector. Its product pipeline includes Vaxonella, which is designed to stimulate immune responses by utilizing the unique properties of the gastrointestinal tract. Additionally, the company is developing vaccines for various infectious diseases, including Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. Prokarium's lead program is aimed at revolutionizing the treatment of bladder cancer by fostering immune-driven, long-lasting antitumor effects, thereby offering new therapeutic options for healthcare providers in combating cancer and infectious diseases.

KAHR Medical Ltd., established in 2005 and headquartered in Jerusalem, Israel, is a biopharmaceutical company specializing in immuno-oncology drug development. It focuses on creating fusion protein pharmaceuticals for treating cancer and autoimmune diseases. KAHR's proprietary technology involves developing 'third generation biological drugs,' which are unique fusion-protein molecules designed to activate immune responses by converting cancer cells' protective mechanisms into targets for the immune system. The company offers several candidates, including DSP105 and DSP106 for T-cell mediated tumor destruction, and DSP107 targeting CD47 tumors while delivering an immune costimulatory signal.

Amarna Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, focused on developing innovative viral vector-based therapies and vaccines. Founded in 2008, the company utilizes its proprietary SVac platform to create next-generation gene and immune therapies targeting a variety of conditions, including allergies, genetic disorders, cancer, and autoimmune diseases. Amarna Therapeutics aims to improve patients' life expectancy and quality of life while also reducing healthcare costs through effective and potentially curative interventions. To achieve its goals, the company has established strategic partnerships with leading research institutions and organizations in virology, vector production, immunology, ophthalmology, oncology, and neurology, fostering collaboration in the advancement of gene therapy technologies.

Empros Pharma AB, established in 2013 and located in Solna, Sweden, focuses on developing pharmaceutical treatments for overweight and obesity. The company's primary product, EMP16, is designed to delay food digestion and absorption in the small intestine while also regulating food intake. Empros Pharma aims to address rising obesity rates, particularly among children and adolescents, by offering innovative oral drug solutions. As the healthcare landscape evolves, with a shift towards embracing pharmaceutical interventions for obesity, Empros Pharma is committed to advancing healthcare through its transformative products that strive to enhance well-being and quality of life.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions through synthetic biology. Established in 2007, Prokarium focuses on creating innovative microbial immunotherapy treatments, particularly in the oncology sector. Its product pipeline includes Vaxonella, which is designed to stimulate immune responses by utilizing the unique properties of the gastrointestinal tract. Additionally, the company is developing vaccines for various infectious diseases, including Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. Prokarium's lead program is aimed at revolutionizing the treatment of bladder cancer by fostering immune-driven, long-lasting antitumor effects, thereby offering new therapeutic options for healthcare providers in combating cancer and infectious diseases.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

KAHR Medical Ltd., established in 2005 and headquartered in Jerusalem, Israel, is a biopharmaceutical company specializing in immuno-oncology drug development. It focuses on creating fusion protein pharmaceuticals for treating cancer and autoimmune diseases. KAHR's proprietary technology involves developing 'third generation biological drugs,' which are unique fusion-protein molecules designed to activate immune responses by converting cancer cells' protective mechanisms into targets for the immune system. The company offers several candidates, including DSP105 and DSP106 for T-cell mediated tumor destruction, and DSP107 targeting CD47 tumors while delivering an immune costimulatory signal.

Empros Pharma AB, established in 2013 and located in Solna, Sweden, focuses on developing pharmaceutical treatments for overweight and obesity. The company's primary product, EMP16, is designed to delay food digestion and absorption in the small intestine while also regulating food intake. Empros Pharma aims to address rising obesity rates, particularly among children and adolescents, by offering innovative oral drug solutions. As the healthcare landscape evolves, with a shift towards embracing pharmaceutical interventions for obesity, Empros Pharma is committed to advancing healthcare through its transformative products that strive to enhance well-being and quality of life.

KAHR Medical Ltd., established in 2005 and headquartered in Jerusalem, Israel, is a biopharmaceutical company specializing in immuno-oncology drug development. It focuses on creating fusion protein pharmaceuticals for treating cancer and autoimmune diseases. KAHR's proprietary technology involves developing 'third generation biological drugs,' which are unique fusion-protein molecules designed to activate immune responses by converting cancer cells' protective mechanisms into targets for the immune system. The company offers several candidates, including DSP105 and DSP106 for T-cell mediated tumor destruction, and DSP107 targeting CD47 tumors while delivering an immune costimulatory signal.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions through synthetic biology. Established in 2007, Prokarium focuses on creating innovative microbial immunotherapy treatments, particularly in the oncology sector. Its product pipeline includes Vaxonella, which is designed to stimulate immune responses by utilizing the unique properties of the gastrointestinal tract. Additionally, the company is developing vaccines for various infectious diseases, including Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. Prokarium's lead program is aimed at revolutionizing the treatment of bladder cancer by fostering immune-driven, long-lasting antitumor effects, thereby offering new therapeutic options for healthcare providers in combating cancer and infectious diseases.